Table 1.
Participant characteristics.
| Total (N = 1133) | Microdosers (n = 953) | Non-microdosers (n = 180) | |
|---|---|---|---|
| Ethnicity | |||
| White* | 85.7% (971) | 86.7% (826) | 80.6% (145) |
| LatinX | 7.8 (88) | 7.3% (70) | 10% (18) |
| Asian | 2.6% (30) | 2.5% (24) | 3.3% (6) |
| Black | 2% (23) | 2% (19) | 2.2% (4) |
| Gender | |||
| Male | 69.7% (788) | 69.7% (663) | 69.4% (125) |
| Female | 29.4% (333) | 29.4% (280) | 29.4% (53) |
| Transgender/non-binary/other | 0.9% (10) | 0.8% (8) | 1.1% (2) |
| Sexual Orientation | |||
| Straight/Heterosexual | 88% (991) | 88.4% (836) | 86.1% (155) |
| LGBTQ2S+ | 12% (135) | 11.6% (110) | 13.9% (25) |
| Age | |||
| 18–24** | 9.4% (107) | 8% (76) | 17.2% (31) |
| 25–54** | 79.2% (897) | 81.5% (777) | 66.7% (120) |
| 55+* | 11.4% (129) | 10.5% (100) | 16.1% (29) |
| Employment | |||
| Full-time* | 59.5% (668) | 60.9% (575) | 52.2% (93) |
| Part-time | 13.6% (153) | 12.9% (122) | 17.4% (31) |
| Student** | 6.9% (77) | 5.9% (56) | 11.8% (21) |
| Other | 20% (224) | 20.2% (191) | 18.5% (33) |
| Income | |||
| Under $10,000 | 4.3% (46) | 4% (36) | 6% (10) |
| $10,000-$29.999 | 16.1% (174) | 15.1% (138) | 21.4% (36) |
| $30,000-$89,999 | 44.7% (482) | 45.4% (414) | 40.5% (68) |
| Above $90,000 | 34.9% (377) | 35.5% (323) | 32.1% (54) |
| Education | |||
| Graduate degree | 18.6% (209) | 17.7% (167) | 23.3% (42) |
| Post-Secondary | 58.8% (662) | 59.6% (563) | 55% (99) |
| Secondary | 21.5% (242) | 21.7% (205) | 20.6% (37) |
| Less than secondary education | 1.1% (12) | 1.1% (10) | 1.1% (2) |
| Community setting | |||
| Suburban | 41.4% (466) | 41.7% (394) | 40% (72) |
| Urban | 40.7% (458) | 40.1% (379) | 43.9% (79) |
| Rural | 17.9% (201) | 18.2% (172) | 16.1% (29) |
| Mental health or substance use problems | 28.5% (316) | 28.9% (269) | 26.3% (47) |
| Microdosing practices | |||
| Dose | |||
| High | 10.6% (101) | ||
| Medium | 72.6% (692) | ||
| Low | 16.8% (160) | ||
| Average monthly microdose days | |||
| 21 days or more | 12.7% (121) | ||
| 11–20 days | 53.4% (509) | ||
| Under 10 days | 33.9% (323) | ||
| Stacking | |||
| Psilocybin only | 40.4% (385) | ||
| Psilocybin & Lion’s Mane | 31.9% (304) | ||
| Psilocybin, Lion’s Mane & Niacin | 27.7% (264) | ||
* = p < .05, ** = p < .01. For variables with missing data, percentages reflect proportions of the total valid, non-missing, responses within a category. Multiple category selection was available to participants for ethnicity and stacking. Dose categories for Psilocybin are as follows: Low ≤ .1 g, Medium = 0.1–0.3 g, High ≥ 0.3 g. For supplementary analyses of stacking microdosers were divided into three groups: psilocybin only (n = 385, 40.4%), psilocybin-HE (n = 304, 31.9%) and psilocybin-HE-B3 (n = 264, 27.7%).